InsightRX

This recent study investigated which factors are associated with receiving pharmacogenetically targeted drugs, and estimated cost-effects of untargeted pre-emptive pharmacogenetic panel testing with a cost–benefit model. Published in Clinical Pharmacology & Therapeutics. https://hubs.ly/Q02ZBjHb0 | #Pharmacogenetics #PrecisionMedicine #CostBenefitModel Kaisa Litonius University of Helsinki Noora Kulla Turun yliopisto - University of Turku American Society for Clinical Pharmacology & Therapeutics

A new study concludes that the combined CKD-EPICR-CYS performs best in terms of predicting pharmacokinetics of pemetrexed. Despite the hypothesized disadvantages, creatinine remains to be a suitable and readily available marker to predict pemetrexed clearance in clinical practice. Published in Cancer Chemotherapy and Pharmacology. https://hubs.ly/Q02Zq1r60 | #Pharmacology #Pharmacokinetics #PrecisionMedicine #OncologyTreatments

A new study addresses if a population physiology-based pharmacokinetic (PBPK) model coupled with a relative transcriptomics approach can predict local anifrolumab tissue concentrations and receptor occupancy, to guide dose selection for phase III anifrolumab studies in new indications. Published in CPT: Pharmacometrics & Systems Pharmacology. https://hubs.ly/Q02Zcn2d0 | #Pharmacokinetics #PrecisionDosing #PBPK Pradeep Sharma National Institute of Pharmaceutical Education and Research American Society for Clinical Pharmacology & Therapeutics

Behind the scenes, pharmacogenomics relies on the dedicated work of stakeholders across the testing and implementation ecosystem to make those promises a reality. The “How to Find a Laboratory of Excellence” conference proceedings, developed by members of the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Initiative offer an exploration into the critical role these stakeholders play in advancing precision medicine. Published in The Pharmacogenomics Journal. https://hubs.ly/Q02YYlkh0 | #PGxTesting #Pharmacogenomics #PrecisionMedicine American Society of Pharmacovigilance Sara Rogers Irma Lerma Rangel College of Pharmacy Springer Nature

Antibiotic and antifungal drugs are valuable tools for treating infections, but any time they are used they can cause side effects and contribute to Antimicrobial Resistance (AR). Learn how the appropriate use of these drugs can help fight AR: https://hubs.ly/Q02Yyw850 #USAAW24 Precision dosing intelligence focuses on determining the right dose of the right drug for each patient at the right time. At InsightRX, we believe that precision dosing extends the benefits of precision medicine to a larger patient population, allowing for individualized treatment plans across a diverse range of widely used medications. By helping clinicians administer the most effective dose, precision dosing also plays a crucial role in minimizing the risk of drug resistance, ensuring that therapies remain effective over time. #USAAW24 #AntimicrobialResistance Centers for Disease Control and Prevention

[Translated] guidelines for Therapeutic Drug Monitoring (TDM) in antibiotics and antifungals in neonates/peds with support for TDM in aminoglycosides, vancomycin, linezolid, beta-lactams, and azoles. Developed jointly by the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Paediatric Infectious Disease (SEIP) and published in Farmacia Hospitalaria. https://hubs.ly/Q02YnkV60 | #TherapeuticDrugMonitoring #Vancomycin #PrecisionMedicine #Bayesian

Even in resource-limited settings, a Bayesian forecasting-based protocl for vancomycin showed cost-benefit outcomes (decrease in AKI rate, lab sampling, and length of hospital stay). Published in Therapeutic Drug Monitoring. https://hubs.ly/Q02Y6sjc0 | #Vancomycin #BayesianForecasting #CostBenefit #VancoProtocols

A case study using Bayesian daptomycin dosing to treat endocarditis in a patient with decreased eGFR. Published in Therapeutic Drug Monitoring. https://hubs.ly/Q02XN5-T0 | #PrecisionMedicine #MIPD #DaptomycinDoses #TherapeuticDrugMonitoring

Our InsightRX team is pleased to announce that we will be presenting research abstracts at ACoP15, which is scheduled for Nov. 10-13 at the Arizona Grand Resort in Phoenix. POSTER PRESENTATIONS #2: 🎙 mipdtrial: an open-source R package for simulating model-informed precision dosing trials 🗓 Monday, November 11, 2024 🕖 7:00 am to 5:00 pm MT Presenter: Jasmine Hughes, Ph.D., Director of Data Science, InsightRX Collaborators: Jordan Brooks, PharmD, Ph.D., Pharmacometrician, InsightRX Ron Keizer Ph.D., PharmD, Chief Scientist, InsightRX Dominic Tong, Ph.D. – Senior Data Scientist, InsightRX Learn more now: https://hubs.ly/Q02Xy5zc0 | #ACoP15 #ACoP2024 #Pharmacometrics #Vancomycin #Pharmacokinetics #MIPD International Society of Pharmacometrics

Our InsightRX team is pleased to announce that we will be presenting research abstracts at ACoP15, which is scheduled for Nov. 10-13 at the Arizona Grand Resort in Phoenix. POSTER PRESENTATION #1: 🎙 Cystatin C complements but does not exceed serum creatinine as a renal function marker: evidence from vancomycin pharmacokinetic model performance in a clinical context 🗓 Monday, November 11, 2024 🕖 7:00 am to 5:00 pm MT Presenter: Dominic Tong, Ph.D., Senior Data Scientist, InsightRX Collaborators: Jasmine Hughes, Ph.D., Director of Data Science, InsightRX Ron Keizer, PharmD, Ph.D., Chief Scientific Officer, InsightRX Learn more now: https://hubs.ly/Q02X9szt0 | #ACoP15 #ACoP2024 #Pharmacometrics #Vancomycin #Pharmacokinetics #MIPD International Society of Pharmacometrics